Improving bone marrow transplants and cell therapies for leukemia and lymphoma
Official title: Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma
Funded at Stanford University · NIH-11197504 · Data updated 2026-11-12
New cell-based treatments and transplant methods aim to make bone marrow transplants safer and help people with leukemia or lymphoma avoid relapse.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | May 1, 1997 |
| Project end | August 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $2,936,016 |
| NIH project number | 2P01CA049605-34A1 |
| Project ID | NIH-11197504 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with leukemia or lymphoma who are eligible for hematopoietic cell transplantation or experimental cell therapy trials would be the main candidates.
✕Less likely to help
People without blood cancers or those who are not eligible for transplants or cell therapy trials are unlikely to benefit directly from this program.
What this research studies
This program focuses on improving bone marrow transplants and cell therapies for people with leukemia and lymphoma. Researchers use animal models, detailed molecular and biological testing, advanced imaging, and coordinated clinical trials to learn how transplants work and why complications like graft-versus-host disease occur. They are testing new immune cell types — including iNKT cells, regulatory T cells, and CAR T cells — plus antibody strategies that target the stem cell antigen CD117 to prevent relapse. The work links lab studies with patient-focused clinical trials at Stanford to try to make transplants safer and more effective.
Why it matters
Potential benefit: If successful, the work could lower transplant risks, reduce graft-versus-host disease, and reduce relapse after transplant for people with blood cancers.
How similar studies have gone: Bone marrow transplant and CAR T-cell therapies have helped many patients, while some components of this program like iNKT and CD117-targeted strategies are newer and less proven.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Negrin, Robert S — Stanford University
- Study coordinator: Negrin, Robert S
Related research
Other NIH-funded projects on the same topics.
-
Bone marrow grafting and cellular therapies for leukemia and lymphoma
A program at Stanford aims to improve bone marrow transplantation and newer cellular therapies to treat blood cancers like leukemia and lymphoma.
-
Inhibiting T-cell Signaling to Treat Adult ATLL
A study to test whether blocking T-cell receptor signaling can help treat adult T-cell leukemia/lymphoma caused by HTLV-1, potentially improving outcomes for patients.
-
Understanding EP300 deficiency in ATLL in adults
This grant explores how loss of EP300 affects an aggressive adult T-cell cancer (ATLL) to identify new ways to help patients.
-
3D gene switches in leukemia and lymphoma
Researchers will map and try to block 3D gene-control hubs that help T-cell leukemia and lymphoma cells grow, aiming to find new ways to help people with these cancers.
-
Targeting T-cell Signals for Adult T-cell Leukemia Lymphoma
This project explores new ways to treat adult T-cell leukemia lymphoma by blocking specific signals within cancer cells.
-
Understanding the causes of Adult T-cell leukemia/lymphoma
This study is looking at Adult T-cell leukemia/lymphoma, a tough cancer that often hits young adults, especially veterans, to find out why some patients don’t respond well to treatment and how we can make those treatments better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.